GRAIL is facing a securities class action lawsuit following a $2.2 billion wipeout in market capitalization in February 2026. The lawsuit alleges that the company misled investors regarding the design and success probability of its NHS-Galleri cancer screening trial. The significant loss occurred after the clinical trial failed to meet its primary endpoint, leading to ongoing investigations by legal firms into the company's disclosures.
